Navigation Links
Another LNA-based RNA Inhibitor Enters Clinical Trials
Date:3/20/2009

COPENHAGEN, March 20 /PRNewswire/ -- Santaris Pharma announced today that the fourth LNA-based drug has been brought into the clinic. In the USA several patients with cancer have now been treated with the Company's Survivin inhibitor, which is jointly developed by Santaris Pharma and Enzon Pharmaceuticals. The U.S. Food and Drug Administration (FDA) recently accepted Enzon Pharma­ceutical's Investigational New Drug (IND) application for the use of the LNA-based Survivin inhibitor.

Survivin is a key protein that controls cancer growth by playing a significant role in cell division, as well as inhibiting the programming that controls cell death. The Survivin inhibitor was developed using the Locked Nucleic Acid technology. In preclinical animal studies, EZN-3042 inhibited Survivin expression and tumor growth. It also potentiated the antitumor activity of taxol, an approved cancer therapeutic.

"Survivin is considered one of the most promising cancer targets and we are pleased that we were able to quickly advance this important compound into patients," said Jeffrey H. Buchalter, chairman and chief executive officer of Enzon Pharmaceuticals.

EZN3042 is one of eight LNA-based RNA inhibitors being developed by Santaris Pharma and Enzon Pharmaceuticals through a comprehensive partnership within the therapeutic area of cancer. Another compound forming part of the collaboration, EZN2968, an LNA-based hif1alfa inhibitor, is currently being investigated in two Phase I/II trials against a variety of cancers. Under the terms of the agreement, Enzon will have exclusive rights to develop and commercialize these compounds in the U.S. and other non-European territories. Santaris Pharma will retain exclusive rights to commercialization in Europe.

"This is the fourth LNA-based drug that has been brought into the clinic in record time either by ourselves or by a partner of ours based on our highly
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Viatronix V3D-Colon Utilized in Another Landmark Study
2. Semafore Achieves a Preclinical Milestone with SF2626, a PI3K-MEK Dual Pathway Kinase Inhibitor
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
5. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
6. Video: Femara(R) First Aromatase Inhibitor to Indicate Survival Benefit Versus Tamoxifen When Taken for Five Years After Breast Cancer Surgery
7. SuperGens PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia
8. New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
9. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
10. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
11. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 /PRNewswire-iReach/ -- The Centers for Medicare & Medicaid ... Network-Quality Improvement Organization (QIN-QIO) contract to a partnership led ... Effective August 1, WVMI will launch Quality Insights Quality ... Pennsylvania , Delaware ... The Network will engage providers and the community in ...
(Date:7/23/2014)... July 23, 2014 Research and ... "Global Electrophysiology Ablation Catheters Market 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Catheter ablation is ... destroy faulty electrical pathways from sections of the ... as cardiac arrhythmias). Cardiac arrhythmias can be of ...
(Date:7/23/2014)... Creekridge Capital, an independent vendor-focused finance ... so far in 2014 to their portfolio of ... from both the healthcare and technology industries. They ... multi-national companies. Each of these new vendors take ... including: standard leasing products, subscription solutions, a dedicated ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 2Global Electrophysiology Ablation Catheters Market 2014-2018: Key Vendors are Boston Scientific, Johnson & Johnson, Medtronic and St. Jude Medical 3Creekridge Capital Signs Several New Vendor Partners 2
... WIRE)--May 30, 2007 - INNOVIVE Pharmaceuticals,Inc. (OTCBB: ... a Phase I,trial of INNO-406, an orally ... or,treatment-intolerant chronic myelogenous leukemia, will be,presented at ... Annual,Meeting. The meeting takes place June 1- ...
... from various,clinical studies including a pivotal Phase III trial ... Nexavar (sorafenib) tablets will be presented at the Annual,Meeting ... USA from June 1 - 5, 2007. , On ... be held on June 4, 2007. Starting at around ...
Cached Medicine Technology:Innovive Pharmaceuticals to Present Interim Data from Phase I Study,of INNO-406 at the American Society of Clinical Oncology Annual,Meeting 2
(Date:7/23/2014)... voice on the recording was low and calm as the speaker ... with the human immunodeficiency virus (HIV) that causes AIDS: “My heart ... I was on the floor flat on my face boohooing, crying ... recording ended less than 10 minutes later. “Don’t feel like this ... is just God setting you up for something greater,” the anonymous ...
(Date:7/23/2014)... By Kathleen Doheny ... (HealthDay News) -- Weight-loss surgery appears to have an ... symptoms in women, according to a new study. ... a weight-loss surgery program reported having incontinence prior to ... their urinary symptoms either improved or disappeared, said study ...
(Date:7/23/2014)... By Amy Norton ... -- The timing of a girl,s first menstrual period may ... a new study suggests. Researchers have identified over ... of menarche -- a woman,s first menstrual period. The researchers ... a number of diseases ranging from type 2 diabetes to ...
(Date:7/23/2014)... genes have been focused on the regions of the ... the form of amino acids thus proteins. But just ... activator which controls the expression and activity of the ... the role exerted such DNA fragment in tumor development. ... in collaboration with the group of Manel Esteller, ...
(Date:7/23/2014)... likelihood of forming false memories, according to research published ... Association for Psychological Science. , In a study conducted ... of California, Irvine and colleagues, sleep-deprived people who viewed ... false information about the photos were more likely to ... were those who got a full night,s sleep. , ...
Breaking Medicine News(10 mins):Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:Gene Study Gives New Insight Into Puberty in Girls 2Health News:Gene Study Gives New Insight Into Puberty in Girls 3Health News:Sleep deprivation may increase susceptibility to false memories 2
... Hospitals that have better working conditions for nurses are ... to a recent report , led by researchers ... are the number six cause of death in the ... workforce in the nation's hospitals, are in a unique ...
... claimed to have developed super-oxidised water, which speeds up ... is made by passing it through a salt membrane ... fungi. ,The company claims that the solution ... ,We would welcome any safe effective treatment which could ...
... has found how medical science could employ aspirin and ... in certain high-risk individuals. ,The study ... Sanford Markowitz at the Ireland Cancer Center. ... mechanism by which the use of aspirin and nonsteroidal ...
... Army hospital here has conducted an accident victim's multiple organ ... to three individuals. ,The retrievals were conducted ... and the organs were transplanted Thursday on two patients at ... ,Donor Ramesh Chand, 60, whose two sons serve ...
... their birth, healthy babies will look you in the eye. ... 9 months, they will exchange smiles. If they ... to worry. ,There is a growing field ... increasingly looking for early signs in babies of autism, attention ...
... Chinese exporters. After the furore over pet food, it is ... under the scanner. ,The federal government has announced ... Food and Drug Administration decides whether the product contains diethylene ... fluid. ,The imports will be released only if ...
Cached Medicine News:Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 2Health News:Better Working Conditions for Nurses Might Decrease Patient Infections 3Health News:Aspirin may Help to Prevent Colon Cancer in High-risk Individuals 2Health News:Army Hospital Conducts First Multiple Organ Retrieval and Transplantation 2Health News:Watch Out for Signs of Autism in Babies! 2Health News:Watch Out for Signs of Autism in Babies! 3Health News:US Halts Import of Chinese Toothpaste 2
All the power and performance of the STS - T but now available with a stand-alone 9" II C-Arm...
... SL1 developed by STORZ MEDICAL is the ... in the field of kidney stone lithotripsy ... requirements to be met by orthopaedic apparatus ... been outlined above. The MINILITH SL1 is ...
... transportable, the Dornier Compact Delta lithotripsy system features ... patient. The systems shock source and C-arm are ... avoid the risk of misalignment. The therapy head ... its motorized lateral and horizontal movement and can ...
Used for temporary urine collection. The leg bag is designed for use with the Non-Adhesive Silicone Condom Catheter. Supplied non-sterile. Reusable. Intended for single patient use only....
Medicine Products: